We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





3D Printing Paves Way for New Type of COVID-19 Lateral Flow Test with More Capabilities

By LabMedica International staff writers
Posted on 11 May 2021
Researchers have developed a 3D printing technique that extends the possibilities of COVID-19 lateral flow tests and enable production of quick, cheap, and easy to use advanced diagnostic tests.

Using a 3D printer, bioengineers at KU Leuven (Leuven, Belgium) have fabricated a 3D version of a lateral flow test. More...
The basis is a small block of porous polymer, in which ‘inks’ with specific properties are printed at precise locations. In this way, a network of channels and small ‘locks’ is printed that let the flow through or block it where and when necessary, without the need for moving parts. During the test, the sample is automatically guided through the different test steps. That way, even complex protocols can be followed.

The researchers evaluated their technique reproducing an ELISA test (Enzyme-Linked Immunosorbent Assay), which is used to detect immunoglobulin E (IgE). Ig E is measured to diagnose allergies. In the lab, this test requires several steps, with different rinses and a change in acidity. The research team was able to run this entire protocol using a printed test kit the size of a thick credit card. The technique not only offers opportunities for cheaper and faster diagnosis in developed countries, but also in countries where the medical infrastructure is less accessible and where there is a strong need for affordable diagnostic tests. The 3D printing technique is also affordable and scalable.

“The great thing about 3D printing is that you can quickly adapt a test’s design to accommodate another protocol, for example, to detect a cancer biomarker. For the 3D printer it does not matter how complex the network of channels is,” said Dr. Cesar Parra. “In our lab, producing the Ig E prototype test costs about USD 1.50, but if we can scale it up, it would be less than USD 1.”

Related Links:
KU Leuven


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.